云顶新耀回应肾病药物“缺货”:2月已提交扩大产能补充申请,期待尽快获得审评批准

澎湃新闻
18 Jul

近期,有患者在社交平台上发帖称,其使用的布地奈德肠溶胶囊(商品名:耐赋康)出现缺货情况。公开信息显示,该药是港股上市药企云顶新耀(1952.HK)旗下产品,是全球首款针对IgA肾病的对因治疗药物,于2024年5月国内上市,并于同年底被纳入2024年国家医保目录。对于缺货情况,7月18日,云顶新耀方面向澎湃新闻记者表示,公司留意到目前耐赋康的情况,并积极应对挑战。公司已于今年2月向国家药监局提交扩大...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10